SurmodicsSRDX
SRDX
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
2% more funds holding
Funds holding: 123 [Q2] → 126 (+3) [Q3]
17.2% less ownership
Funds ownership: 100.66% [Q2] → 83.47% (-17.2%) [Q3]
24% less capital invested
Capital invested by funds: $604M [Q2] → $459M (-$145M) [Q3]
74% less call options, than puts
Call options by funds: $135K | Put options by funds: $527K
75% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 1 (-3) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for SRDX.
Financial journalist opinion
Based on 4 articles about SRDX published over the past 30 days
Negative
Zacks Investment Research
6 days ago
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Zacks Investment Research
2 weeks ago
SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
2 weeks ago
Best Momentum Stocks to Buy for January 3rd
SRDX and CWAN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
Positive
Zacks Investment Research
2 weeks ago
New Strong Buy Stocks for January 3rd
UAA, BRBR, RBA, SRDX and CTRA have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
Positive
Zacks Investment Research
1 month ago
Why Is SurModics (SRDX) Up 4% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
Positive
Zacks Investment Research
2 months ago
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.
Positive
Zacks Investment Research
2 months ago
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Negative
Zacks Investment Research
2 months ago
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago.
Neutral
Business Wire
2 months ago
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary Total Revenue of $33.2 million, an increase of 19% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”) license fee revenue(1) of $31.3 million, an increase of 1.
Neutral
Business Wire
2 months ago
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C. PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmodics Pounce™.
Charts implemented using Lightweight Charts™